OA17 Patient values and what matters to patients with axial spondyloarthritis in clinic
نویسندگان
چکیده
Abstract Background/Aims Physician-patient discrepancy in the goals of treatment remains an issue axial spondyloarthritis (AxSpA). The National Axial Spondyloarthritis Society (NASS) has recently launched a national survey on patient values. Bridging gap and improving alignment physician-patient may lead to better outcomes. objectives this study were investigate what patients wanted discuss prior their clinic attendance explore if these topics discussed by physician. discrepancies between physician reviewed steps put place bridge gap. Methods Patients fulfilled ASAS criteria for AxSpA. At baseline 130 consecutive attending AxSpA April December 2021 sent pre-clinic questionnaire. asked 2 questions were: 1) What do you wish at your appointment? 2) achieve following treatment? Questionnaires collected clinic. medical notes letters then post-clinic check 1 discussed. demographics disease activity scores BASMI, BASFI BASDAI also collected. Results baseline, 100/130 (77%) returned questionnaire mean age was 41 years (range 23-67). 74 (74%) male 80 (80%) work. seen doctor (38%), specialist nurse (32%) physiotherapist (30%). In terms treatment, currently biologics (64%), NSAIDs (46%) DMARDs BASMI 1.6 0.2-5.4), 2.7 (0-9.2), 3.5 (0.2-8.6) CRP 3 (0-20). For question 1, top three medication, pain management progression disease. 2, be pain-free, maintain flexibility being mobile active. There other that raised including fatigue, sleep, infections family planning. Post clinic, directly 73% 59% cases. most exercise pain. Pooling topics, five themes pain, flexibility, progression. A limitation is post analysis based written letters. Conclusion This confirms degree discordance goals. To gap, we are now focused they hope from treatment. We have updated our pathway include topics. Understanding will help us develop content interventions educational programmes improve clinical Disclosure A. Chan: None. Suarez: K. Rigler: J. Hamilton:
منابع مشابه
Patient Burden of Axial Spondyloarthritis
Axial spondyloarthritis (AxSpA) is an inflammatory spondyloarthritis (SpA) that has significant impact on a patient's life. Symptoms, including fatigue, sleep problems, depression, and sexual dysfunction, can profoundly impact health-related quality of life (HRQoL) and limit work, leisure, and daily activities. Available therapies effectively manage pain and inflammation in early-stage disease,...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Immunohistological analysis of active sacroiliitis in patients with axial spondyloarthritis
The sacroiliac joints (SIJs) are one of the most common sites involved in axial spondyloarthritis (axSpA), and there are few studies on the histopathology of the SIJ in this group of patients.Mononuclear cell infiltrates in the bone marrow and fibrous tissue resembling a pannus formation were the pathological features of early sacroiliitis in our previous study. We undertook a further immunohis...
متن کاملImpact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
OBJECTIVE Patient-reported outcomes (PROs) provide an opportunity to collect important information relating to patient well-being, which is often difficult for physicians to measure (e.g., quality of life, pain, fatigue, and sleep). Here we evaluate the effects of certolizumab pegol (CZP) on PROs during the 24-week, double-blind phase of the RAPID axial spondyloarthritis (SpA) trial, a phase 3 ...
متن کاملNSAIDs in axial spondyloarthritis: to be continued…?
Phenylbutazone was discovered in 1946 and promptly exhibited efficacy in various rheumatic diseases in the early 1950s. Its efficacy on pain and general well-being was especially present in ankylosing spondylitis (AS), which was then known as ‘rheumatoid spondylitis’. 2 However, even in the early days, non-steroidal antiinflammatory drugs (NSAIDs) were not considered harmless drugs, as the toxi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2023
ISSN: ['1462-0324', '1462-0332']
DOI: https://doi.org/10.1093/rheumatology/kead104.017